InSphero at the SOT 2025
Join us at the SOT 2025 in Orlando, Florida. This premier event for toxicology professionals is the perfect opportunity to explore the latest advancements in the field. Visit our booth #1211 to discover how our innovative solutions transform toxicological research and drive safety and sustainability progress.
Don’t miss out on all the exciting activities we’ve planned during SOT 2025, happening from Sunday, March 16, to Thursday, March 20. We can’t wait to connect with you there!
Meet our Team at the SOT 2025
Jan Lichtenberg, PhD
CEO and Co-Founder
Jan Lichtenberg, PhD
CEO and Co-Founder
Madhu Nag, PhD
Chief Scientific Officer
Madhu Nag, PhD
Chief Scientific Officer
Bruno Filippi, PhD
Vice President, Liver Safety
Bruno Filippi, PhD
Vice President, Liver Safety
Arumugham (Ragoo) Raghunathan, PhD
Senior Director Business Development
Arumugham (Ragoo) Raghunathan, PhD
Senior Director Business Development
Arnab China, PhD
Business Development Manager
Arnab China, PhD
Business Development Manager
Our Booth at the SOT 2025
Visit our booth #1211 and discover our 3D InSight™ Liver Safety - Practical, Physiological & Cost-effective 3D In Vitro Solutions for DILI Assessment
Poster at the SOT 2025
Physiological liver microtissue 384-well microplate system for preclinical hepatotoxicity assessment of therapeutic small molecule drugs
Date: Monday, 17 March, 2025 | 9:15 - 11:45 AM
Poster number: 3264
Bruno Filippi, PhD
Vice President, Liver Safety
Bruno Filippi, PhD
Vice President, Liver Safety
Exhibitor-Hosted Session at the SOT 2025
The 3D InSight™ Liver Microtissues Platform: a Versatile Tool for In Vitro Hepatotoxicity Studies
Date: Wednesday, 19 March, 2025 | 12:15 - 1:15 PM
Location: W208A
The 3D InSight™ Liver Microtissue technology enables the large-scale production of miniaturized and standardized liver spheroids made of primary hepatocytes and non-parenchymal liver cells. The 3D InSight™ Liver Microtissue is a versatile micro-physiological liver system to perform hepatotoxicity studies during the entire drug discovery and development process, from initial screenings of large compound sets to detailed investigations aiming at uncovering mechanisms of toxicity. The utility of liver microtissues in the drug development process will also be exemplified by Piyush Bajaj, distinguished scientist working in the investigative toxicology department at Sanofi, in a presentation on how liver microtissues played a key role in the derisking of Amcenestrant, an investigational oral selective estrogen receptor degrader currently being evaluated for the treatment of breast cancer.
Bruno Filippi, PhD
Vice President, Liver Safety
Bruno Filippi, PhD
Vice President, Liver Safety